<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Anker, Stefan D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Mid-Regional Pro-Adrenomedullin Test Predicts 90-Day Mortality after Heart Failure</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">A novel biomarker, mid-regional pro-adrenomedullin (MR-proADM), has been shown to predict mortality among patients with heart failure better than the established biomarkers for prognosis that currently are available. MR-proADM was compared with brain natriuretic peptide (BNP) and NT-proBNP (a biologic fragment associated with BNP) in the BACH trial [NCT00537628], which is the largest biomarker study to be done in the setting of suspected heart failure.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>